huahaipharm(SH:600521)2022-04-25 16:00Financial Performance - The company's operating revenue for Q1 2022 was RMB 1,772,607,601.98, representing an increase of 18.42% compared to the same period last year[4] - The net profit attributable to shareholders of the listed company was RMB 137,701,672.91, a decrease of 46.02% year-on-year[4] - The company's diluted earnings per share for the period was RMB 0.10, down 41.18% from the same period last year[4] - Net profit for Q1 2022 was CNY 139.88 million, a decrease of 46% from CNY 259.72 million in Q1 2021[17] - The total profit before tax was CNY 197.93 million, down from CNY 331.81 million in the same quarter of the previous year, representing a decline of 40.2%[17] - The total comprehensive income for Q1 2022 was CNY 139.78 million, down from CNY 260.17 million in the same period last year[18] Cash Flow - The net cash flow from operating activities was RMB 101,134,514.53, showing a significant increase of 56.38% compared to the previous year[4] - Cash flow from operating activities generated a net amount of CNY 101.13 million, compared to CNY 64.67 million in Q1 2021, reflecting a 56.4% increase[20] - Net cash flow from investing activities was -$557.99 million, compared to -$415.82 million in the previous period, indicating an increase in cash outflow[21] - Cash inflow from financing activities totaled $1.01 billion, up from $478.34 million year-over-year, reflecting a significant increase in borrowing[21] - Net cash flow from financing activities was $328.87 million, a turnaround from a negative $159.60 million in the previous period[21] - The net decrease in cash and cash equivalents was -$133.19 million, an improvement from -$510.41 million in the prior period[21] - The ending balance of cash and cash equivalents stood at $1.72 billion, compared to $1.69 billion at the end of the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were RMB 15,920,304,326.53, reflecting a 2.92% increase from the end of the previous year[5] - Current assets totaled CNY 6,886,761,651.71 as of March 31, 2022, compared to CNY 6,812,609,308.04 at the end of 2021, reflecting a slight increase[13] - Total liabilities increased to CNY 9,002,635,838.03 in Q1 2022 from CNY 8,691,800,745.73 in Q4 2021, reflecting a rise of 3.6%[15] - The company experienced a significant decrease in contract liabilities, which fell by 39.89% to RMB 40,101,810.94 due to reduced advance payments[7] Equity and Shareholder Information - The company’s total equity attributable to shareholders was RMB 6,697,648,842.25, an increase of 2.12% from the previous year[5] - The company reported a total of 98,103 common shareholders at the end of the reporting period[9] - The company's equity attributable to shareholders reached CNY 6,697,648,842.25 in Q1 2022, compared to CNY 6,558,842,119.10 in Q4 2021, an increase of 2.1%[15] Research and Development - Research and development expenses increased to RMB 217,360,827.03, up 41.88% year-on-year, driven by advancements in biopharmaceuticals and new drug projects[8] - Research and development expenses rose to CNY 217.36 million, up 42% from CNY 153.20 million in the same period last year[17] Inventory and Receivables - Inventory increased to CNY 2,918,279,685.85 in Q1 2022 from CNY 2,738,528,577.05 in Q4 2021, indicating a growth of 6.6%[13] - Accounts receivable stood at CNY 1,799,037,564.23 in Q1 2022, slightly down from CNY 1,849,743,324.64 in Q4 2021, a decrease of 2.7%[13]